atazanavir sulfate

Summary

Summary: An azapeptide and HIV-PROTEASE INHIBITOR that is used in the treatment of HIV INFECTIONS and AIDS in combination with other ANTI-HIV AGENTS.

Top Publications

  1. Beckman J, Wood B, Ard K, Price C, Solomon D, Zuflacht J, et al. Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir. PLoS ONE. 2017;12:e0181993 pubmed publisher
    ..Atazanavir does not improve endothelial function of conduit arteries. ClinicalTrials.gov NCT03019783. ..
  2. Bierman W, van Agtmael M, Nijhuis M, Danner S, Boucher C. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS. 2009;23:279-91 pubmed publisher
    ..Arguments for this strategy are NRTI/NNRTI side effects, NRTI/NNRTI resistance, and costs. ..
  3. Fabbiani M, Bracciale L, Doino M, D Avino A, Marzocchetti A, Navarra P, et al. Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients. J Infect. 2011;62:319-21 pubmed publisher
  4. Svärd J, Mugusi S, Mloka D, Neogi U, Meini G, Mugusi F, et al. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. PLoS ONE. 2017;12:e0178942 pubmed publisher
    ..The introduction of regular virological monitoring should be prioritized and integrated with drug resistance studies in resource limited settings. ..
  5. Barzi M, Pankowicz F, Zorman B, Liu X, Legras X, Yang D, et al. A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism. Nat Commun. 2017;8:39 pubmed publisher
    ..Here the authors generate mice lacking the Por gene in the liver, and show that human cytochrome metabolism is used following repopulation with human hepatocytes. ..
  6. Ongubo D, Lim R, Tweya H, Stanley C, Tembo P, Broadhurst R, et al. A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi. BMC Infect Dis. 2017;17:461 pubmed publisher
    ..Drug resistance testing targeted for patients with virological failure despite elevated bilirubin levels would facilitate timely switch to third line antiretroviral regimens whenever available. ..
  7. López Galera R, Ribera Pascuet E, Esteban Mur J, Montoro Ronsano J, Juarez Gimenez J. Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir. Eur J Clin Pharmacol. 2008;64:1235-6 pubmed publisher
  8. Lennox J, Landovitz R, Ribaudo H, Ofotokun I, Na L, Godfrey C, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014;161:461-71 pubmed publisher
    ..Tolerability of regimens containing raltegravir or ritonavir-boosted darunavir was superior to that of the ritonavir-boosted atazanavir regimen. National Institute of Allergy and Infectious Diseases. ..
  9. Hamzah L, Campbell L, Wandolo E, Engler B, Cheserem E, Naftalin C, et al. Changes in kidney function in patients with suppressed HIV RNA who substitute their protease inhibitor with atazanavir/ritonavir. AIDS. 2015;29:392-4 pubmed publisher

More Information

Publications16

  1. Gong Y, Robinson B, Rose R, Deminie C, Spicer T, Stock D, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother. 2000;44:2319-26 pubmed
    ..Taken together, our data suggest that BMS-232632 may be a valuable protease inhibitor for use in combination therapy. ..
  2. Dalla Vechia L, Reichart B, Glasnov T, Miranda L, Kappe C, De Souza R. A three step continuous flow synthesis of the biaryl unit of the HIV protease inhibitor Atazanavir. Org Biomol Chem. 2013;11:6806-13 pubmed publisher
    ..The synthesis involved Pd-catalyzed Suzuki–Miyaura cross-coupling, followed by hydrazone formation and a subsequent hydrogenation step, and additionally incorporates a liquid–liquid extraction step. ..
  3. Xiang N, James M, Walters S, Bamford A, Foster C. Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir: an 18-month retrospective study. HIV Med. 2014;15:635-6 pubmed publisher
  4. Postorino M, Prosperi M, Focà E, Quiros Roldan E, Di Filippo E, Maggiolo F, et al. Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort. BMC Infect Dis. 2017;17:212 pubmed publisher
    ..Interestingly, high levels of inflammation measured through NLR, were also associated with clinical events. So, these patients should be monitored more strictly. ..
  5. Antoniou T, Szadkowski L, Walmsley S, Cooper C, Burchell A, Bayoumi A, et al. Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients. BMC Infect Dis. 2017;17:266 pubmed publisher
  6. Chawana T, Gandhi M, Nathoo K, Ngara B, Louie A, Horng H, et al. Defining a Cutoff for Atazanavir in Hair Samples Associated With Virological Failure Among Adolescents Failing Second-Line Antiretroviral Treatment. J Acquir Immune Defic Syndr. 2017;76:55-59 pubmed publisher
    ..Male sex and better self-reported adherence were associated with adequate atazanavir hair concentrations. Antiretroviral hair concentrations may serve as a useful clinical tool among adolescents. ..
  7. Santoriello D, Al Nabulsi M, Reddy A, Salamera J, D Agati V, Markowitz G. Atazanavir-Associated Crystalline Nephropathy. Am J Kidney Dis. 2017;70:576-580 pubmed publisher
    ..Recognition of this association and prompt withdrawal of the offending agent are critical to optimize outcomes. ..